Skip to main content

CORRECTION article

Front. Oncol., 04 August 2022
Sec. Pharmacology of Anti-Cancer Drugs
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.995352
This article is part of the Research Topic Therapeutic Drug Monitoring and Clinical Toxicology of Anti-Cancer Drugs, volume II View all 13 articles

Corrigendum: The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: A SEER population-based analysis

Qi Lin&#x;Qi Lin1†Jia-Hao Bao&#x;Jia-Hao Bao2†Fei XueFei Xue1Jia-Jun QinJia-Jun Qin1Zhen ChenZhen Chen1Zhong-Rong ChenZhong-Rong Chen1Chao LiChao Li1Yi-Xuan YanYi-Xuan Yan2Jin Fu*&#x;Jin Fu1*‡Zhao-Li Shen*&#x;Zhao-Li Shen1*‡Xian-Zhen Chen*&#x;Xian-Zhen Chen1*‡
  • 1Department of Neurosurgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
  • 2Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China

A corrigendum on
The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: A SEER population-based analysis

By Lin Q, Bao J-H, Xue F, Qin J-J, Chen Z, Chen Z-R, Li C, Yan Y-X, Fu J, Shen Z-L and Chen X-Z (2022) 12:870843. doi: 10.3389/fonc.2022.870843

In the published article, there was an error in affiliation 1. Instead of “1Department of Neurosurgery, School of Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China”, it should be “Department of Neurosurgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China” as above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: anaplastic astrocytoma, chemotherapy, SEER, heart disease-related death, cardio-oncology

Citation: Lin Q, Bao J-H, Xue F, Qin J-J, Chen Z, Chen Z-R, Li C, Yan Y-X, Fu J, Shen Z-L and Chen X-Z (2022) Corrigendum: The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: A SEER population-based analysis. Front. Oncol. 12:995352. doi: 10.3389/fonc.2022.995352

Received: 15 July 2022; Accepted: 19 July 2022;
Published: 04 August 2022.

Approved by:

Frontiers Editorial Office, Media SA, Switzerland

Copyright © 2022 Lin, Bao, Xue, Qin, Chen, Chen, Li, Yan, Fu, Shen and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xian-Zhen Chen, Chenchenxianzheny@126.com; Zhao-Li Shen, Shenleelies@sina.com; Jin Fu, fujin@tongji.edu.cn

† These authors have contributed equally to this work and share first authorship

‡ These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.